Medlive Technology Co (HKSE:02192) ROCE % : 6.43% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medlive Technology Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 6.43%.

Medlive Technology Co ROCE % Historical Data

The historical data trend for Medlive Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co ROCE % Chart

Medlive Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

68.28

92.33

3.39

3.06

5.47

Medlive Technology Co Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					3.22	1.63	4.55	4.46	6.43

Medlive Technology Co ROCE % Calculation

Medlive Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	277.265	/	( ( (5140.494 - 148.239)	+	(5352.753 - 207.569) )	/ 2 )
	=	277.265	/	( (4992.255	+	5145.184)	/ 2 )
	=	277.265	/	5068.7195
	=	5.47 %

Medlive Technology Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	329.522	/	( ( (5340.653 - 236.08)	+	(5352.753 - 207.569) )	/ 2 )
	=	329.522	/	( ( 5104.573	+	5145.184 )	/ 2 )
	=	329.522	/	5124.8785
	=	6.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Medlive Technology Co (HKSE:02192) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medlive Technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlive Technology Co (HKSE:02192) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN

Website

https://www.medlive.cn

Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.

Medlive Technology Co (HKSE:02192) Headlines

No Headlines